P. Kantharidis

A. Shah, M. Cooper, K. Sourris, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines

J. Zalcberg, P. Kantharidis, J. Parisot, 2000, Prostate Cancer and Prostatic Diseases.

The Role of Advanced Glycation in Reduced Organic Cation Transport Associated with Experimental Diabetes

Merlin C. Thomas, Merlin C Thomas, M. Cooper, 2004, Journal of Pharmacology and Experimental Therapeutics.

Advanced Glycation – New AGE Focus for Diabetes

Merlin C Thomas, M. Cooper, P. Kantharidis, 2004 .

Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop.

Merlin C. Thomas, Merlin C Thomas, G. Zauli, 2011, Atherosclerosis.

Physical mapping of a tandem duplication on the long arm of chromosome 7 associated with a multidrug resistant phenotype.

S. Scherer, L. Tsui, M. de Silva, 1999, Cancer genetics and cytogenetics.

Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line

L. Campbell, J. Zalcberg, P. Kantharidis, 1994, International journal of cancer.

Absolute quantitation of MDR1 transcripts using heterologous DNA standards--validation of the competitive RT-PCR (CRT-PCR) approach.

J. Zalcberg, A. El-Osta, P. Kantharidis, 1999, BioTechniques.

Inheritance of chromosome 7 is associated with a drug-resistant phenotype in somatic cell hybrids.

M. de Silva, L. Campbell, J. Zalcberg, 1996, British Journal of Cancer.

Analogues and Cytosine Arabinoside in Myeloid Leukemia Altered Multidrug Resistance Phenotype Caused by Anthracycline

J. Zalcberg, D. Rischin, P. Kantharidis, 2013 .

Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.

J. Zalcberg, D. Rischin, P. Kantharidis, 1999, Blood.

Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line.

J. Zalcberg, P. Kantharidis, X. Hu, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis

Merlin C. Thomas, Merlin C Thomas, M. Cooper, 2018, Diabetes.

The role of EMT in renal fibrosis

P. Kantharidis, Rosemarie M. Carew, Bo Wang, 2011, Cell and Tissue Research.

Reduced tubular cation transport in diabetes: prevented by ACE inhibition.

Merlin C. Thomas, Merlin C Thomas, G. Jerums, 2003, Kidney international.

Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function

M. Cooper, E. Brennan, P. Kantharidis, 2021, Nature Reviews Nephrology.

Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis

M. Cooper, E. Brennan, C. Tikellis, 2018, Diabetes.

Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis

M. Cooper, E. Brennan, C. Tikellis, 2017, Diabetes.

Advanced glycation end products as environmental risk factors for the development of type 1 diabetes.

J. Forbes, P. Kantharidis, M. Coughlan, 2012, Current drug targets.

Precipitous Release of Methyl-CpG Binding Protein 2 and Histone Deacetylase 1 from the Methylated Human Multidrug Resistance Gene (MDR1) on Activation

A. Wolffe, J. Zalcberg, A. El-Osta, 2002, Molecular and Cellular Biology.

Regulation of MDR1 gene expression: emerging concepts.

J. Zalcberg, P. Kantharidis, X. Hu, 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.

J. Zalcberg, A. El-Osta, P. Kantharidis, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

MicroRNAs as Biomarkers of Diabetic Nephropathy

P. Kantharidis, A. McClelland, 2015 .

Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs

Yusuke Suzuki, H. Sakuma, P. Kantharidis, 2020, Frontiers in Pharmacology.

Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b.

Merlin C. Thomas, M. Cooper, P. Kantharidis, 2014, Kidney international.

MicroRNA in Diabetic Nephropathy: Renin Angiotensin, AGE/RAGE, and Oxidative Stress Pathway

P. Kantharidis, Shinji Hagiwara, A. McClelland, 2013, Journal of diabetes research.

Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis.

Merlin C. Thomas, M. Cooper, R. Komers, 2012, Journal of the American Society of Nephrology : JASN.

E-Cadherin Expression Is Regulated by miR-192/215 by a Mechanism That Is Independent of the Profibrotic Effects of Transforming Growth Factor-β

G. Goodall, M. Cooper, M. Saleem, 2010, Diabetes.

Diabetes Complications: The MicroRNA Perspective

Bo Wang, P. Kantharidis, H. Lan, 2011, Diabetes.

miR-200a Prevents Renal Fibrogenesis Through Repression of TGF-β2 Expression

Merlin C. Thomas, M. Cooper, W. Burns, 2010, Diabetes.

TGF-β Regulates miR-206 and miR-29 to Control Myogenic Differentiation through Regulation of HDAC4

P. Kantharidis, C. Winbanks, P. Gregorevic, 2011, The Journal of Biological Chemistry.

and ) on Activation MDR 1 Gene ( the Methylated Human Multidrug Resistance Protein 2 and Histone Deacetylase 1 from Precipitous Release of Methyl-CpG Binding

A. Wolffe, J. Zalcberg, A. El-Osta, 2002 .

The Use of Targeted Next Generation Sequencing to Explore Candidate Regulators of TGF-β1’s Impact on Kidney Cells

Haroon Naeem, Junwen Wang, G. Ji, 2018, Front. Physiol..

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line

J. Zalcberg, D. Rischin, P. Kantharidis, 1999, British Journal of Cancer.

microRNA in the development of diabetic complications.

P. Kantharidis, A. McClelland, 2014, Clinical science.

C-terminal domain of insulin-like growth factor (IGF) binding protein-6: structure and interaction with IGF-II.

R. Norton, S. Yao, P. Kantharidis, 2004, Molecular endocrinology.

Expression of mdr1 and mrp in the normal B‐cell homologue of B‐cell chronic lymphocytic leukaemia

J. Zalcberg, P. Kantharidis, D. Tzelepis, 1997, British journal of haematology.

Diabetic Nephropathy: Proteinuria, Inflammation, and Fibrosis

L. Gnudi, P. Kantharidis, S. Zheng, 2016, Journal of diabetes research.

Where are we in diabetic nephropathy: microRNAs and biomarkers?

P. Kantharidis, Shinji Hagiwara, A. McClelland, 2014, Current opinion in nephrology and hypertension.

Transcriptome-Based Analysis of Kidney Gene Expression Changes Associated with Diabetes in OVE26 Mice, in the Presence and Absence of Losartan Treatment

R. Komers, D. Cohen, P. Kantharidis, 2014, PloS one.

What Are New Avenues for Renal Protection, in Addition to RAAS Inhibition?

M. Cooper, P. Kantharidis, Shinji Hagiwara, 2012, Current Hypertension Reports.

miRNAs in the Pathophysiology of Diabetes and Their Value as Biomarkers

E. Brennan, P. Kantharidis, C. Godson, 2016 .

Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease.

M. Cooper, E. Brennan, A. El-Osta, 2018, Journal of the American Society of Nephrology : JASN.

Study of microRNA in diabetic nephropathy: Isolation, quantification and biological function

E. Brennan, P. Kantharidis, Shinji Hagiwara, 2015, Nephrology.

Magnetic silica spheres with large nanopores for nucleic acid adsorption and cellular uptake.

G. Lu, A. Middelberg, Tingting Liu, 2012, Biomaterials.

Specialized pro-resolving mediators in diabetes: novel therapeutic strategies.

E. Brennan, P. Kantharidis, Madhura Bose, 2019, Clinical science.

C-terminal domain of insulin-like growth factor binding protein-6: structure and interaction with insulin-like growth factor-II

R. Norton, S. Yao, P. Kantharidis, 2004 .

Increased liver AGEs induce hepatic injury mediated through an OST48 pathway

M. Febbraio, P. Angus, K. Sourris, 2017, Scientific Reports.

Nucleotide sequence of UK bovine rotavirus segment 4: possible host restriction of VP3 genes.

M. Dyall-Smith, P. Kantharidis, G. Tregear, 1988, Virology.

Quantitative gene expression analysis in kidney tissues.

W. Burns, C. Tikellis, P. Kantharidis, 2009, Methods in molecular biology.

Ameliorating diabetes-associated atherosclerosis and diabetic nephropathy through modulation of soluble guanylate cyclase

J. D. de Haan, P. Kantharidis, L. Dietz, 2023, Frontiers in cardiovascular medicine.

miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7.

R. Komers, P. Kantharidis, C. Winbanks, 2015, Clinical science.

Potential of Modulating Aldosterone Signaling and Mineralocorticoid Receptor with microRNAs to Attenuate Diabetic Kidney Disease

P. Kantharidis, T. Gohda, Shinji Hagiwara, 2024, International journal of molecular sciences.

Magnetic silica spheres with large nanopores for nucleic acid adsorption and cellular uptake.

G. Lu, A. Middelberg, Jian Liu, 2012, Biomaterials.

Increased liver AGEs induce hepatic injury mediated through an OST48 pathway

M. Febbraio, P. Angus, K. Sourris, 2017, Scientific Reports.

Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.

K. Sourris, A. El-Osta, P. Kantharidis, 2023, Kidney international.